We are live on ! Find out more

IRLA

IRulya Therapeutics Inc. Common Stock

IRLA

Market cap $33M

32.40 USD

0.00

0%

1 day

0%

5 days

21.17%

1 month

13.33%

3 months

87.83%

6 months

14.89%

Year to date

-94.6%

1 year

-91.73%

5 years

-99.78%

10 years

-99.51%

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Keith R.

Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript

Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript

Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious, underserved diseases, today announced that it will host a virtual key opinion leader (KOL) event on Monday, September 28, 2026 from 12:30-2:00 PM ET.

Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

Quince Therapeutics to Participate in September 2026 Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced that senior management will participate in the following investor conferences in September 2026:

Quince Therapeutics to Participate in September 2026 Investor Conferences

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced the formation of a Scientific Advisory Board (SAB) of leading clinicians to support the advancement of LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor) designed to enhance pulmonary delivery and reduce systemic exposure.

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript

Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript

Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX) announced Phase 2a data evaluating LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), presented at the American Thoracic Society (ATS) conference in Orlando. The Company recently acquired LAM-001 through its previously announced acquisition of Orphai Therapeutics, Inc., a clinical-stage biotechnology company developing LAM-001 to treat rare pulmonary diseases

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

See News Rankings

Price charts implemented using Lightweight Charts™